Loading...

Orville Kolterman

TitleClinical Professor
InstitutionUniversity of California San Diego
DepartmentMedicine
Address9500 Gilman Drive #0835
La Jolla CA 92093
Phone858-534-5463
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    DIABETES CONTROL AND COMPLICATIONS TRIAL
    NIH/NIDDK U01DK037828Jul 23, 1986 - Jun 30, 1994
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Riddle MC, Yuen KC, de Bruin TW, Herrmann K, Xu J, Öhman P, Kolterman O. Fixed ratio dosing of pramlintide with regular insulin before a standard meal in patients with type 1 diabetes. Diabetes Obes Metab. 2015 Sep; 17(9):904-7. PMID: 26040429; PMCID: PMC4758401.
    2. MacConell L, Gurney K, Malloy J, Zhou M, Kolterman O. Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients. Diabetes Metab Syndr Obes. 2015; 8:241-53. PMID: 26056482; PMCID: PMC4445788.
    3. Miao F, Chen Z, Genuth S, Paterson A, Zhang L, Wu X, Li SM, Cleary P, Riggs A, Harlan DM, Lorenzi G, Kolterman O, Sun W, Lachin JM, Natarajan R. Evaluating the role of epigenetic histone modifications in the metabolic memory of type 1 diabetes. Diabetes. 2014 May; 63(5):1748-62. PMID: 24458354; PMCID: PMC3994951.
    4. Micheletto F, Dalla Man C, Kolterman O, Chiquette E, Herrmann K, Schirra J, Kovatchev B, Cobelli C. In silico design of optimal ratio for co-administration of pramlintide and insulin in type 1 diabetes. Diabetes Technol Ther. 2013 Oct; 15(10):802-9. PMID: 23865841; PMCID: PMC3781117.
    5. Herrmann K, Frias JP, Edelman SV, Lutz K, Shan K, Chen S, Maggs D, Kolterman O. Pramlintide improved measures of glycemic control and body weight in patients with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy. Postgrad Med. 2013 May; 125(3):136-44. PMID: 23748514.
      View in: PubMed
    6. Riddle M, Frias J, Zhang B, Maier H, Brown C, Lutz K, Kolterman O. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. Diabetes Care. 2007 Nov; 30(11):2794-9. PMID: 17698615.
      View in: PubMed
    7. Grasela TH, Dement CW, Kolterman O, Fineman MS, Grasela DM, Honig P, Antal EJ, Bjornsson TD, Loh E. Pharmacometrics and the transition to model-based development. Clin Pharmacol Ther. 2007 Aug; 82(2):137-42. PMID: 17632539.
      View in: PubMed
    8. Edelman SV, Garg S, Kolterman O. Is pramlintide a safe and effective adjunct therapy for patients with type 1 diabetes? Nat Clin Pract Endocrinol Metab. 2007 May; 3(5):E1; discussion E2. PMID: 17452962.
      View in: PubMed
    9. Marrero DG, Crean J, Zhang B, Kellmeyer T, Gloster M, Herrmann K, Rubin R, Fineberg N, Kolterman O. Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes. Diabetes Care. 2007 Feb; 30(2):210-6. PMID: 17259483.
      View in: PubMed
    10. Edelman S, Garg S, Frias J, Maggs D, Wang Y, Zhang B, Strobel S, Lutz K, Kolterman O. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care. 2006 Oct; 29(10):2189-95. PMID: 17003291.
      View in: PubMed
    11. Schnabel CA, Wintle M, Kolterman O. Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes. Vasc Health Risk Manag. 2006; 2(1):69-77. PMID: 17319471; PMCID: PMC1993968.
    12. Amiel SA, Heller SR, Macdonald IA, Schwartz SL, Klaff LJ, Ruggles JA, Weyer C, Kolterman O, Maggs DG. The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetes. Diabetes Obes Metab. 2005 Sep; 7(5):504-16. PMID: 16050943.
      View in: PubMed
    13. Weyer C, Fineman MS, Strobel S, Shen L, Data J, Kolterman O, Sylvestri MF. Properties of pramlintide and insulin upon mixing. Am J Health Syst Pharm. 2005 Apr 15; 62(8):816-22. PMID: 15821274.
      View in: PubMed
    14. Ratner R, Whitehouse F, Fineman MS, Strobel S, Shen L, Maggs DG, Kolterman O, Weyer C. Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets. Exp Clin Endocrinol Diabetes. 2005 Apr; 113(4):199-204. PMID: 15891954.
      View in: PubMed
    15. Kolterman O, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, Baron AD. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm. 2005 Jan 15; 62(2):173-81. PMID: 15700891.
      View in: PubMed
    16. Ratner RE, Dickey R, Fineman M, Maggs DG, Shen L, Strobel SA, Weyer C, Kolterman O. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med. 2004 Nov; 21(11):1204-12. PMID: 15498087.
      View in: PubMed
    17. Heise T, Heinemann L, Heller S, Weyer C, Wang Y, Strobel S, Kolterman O, Maggs D. Effect of pramlintide on symptom, catecholamine, and glucagon responses to hypoglycemia in healthy subjects. Metabolism. 2004 Sep; 53(9):1227-32. PMID: 15334389.
      View in: PubMed
    18. Hollander P, Maggs DG, Ruggles JA, Fineman M, Shen L, Kolterman O, Weyer C. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res. 2004 Apr; 12(4):661-8. PMID: 15090634.
      View in: PubMed
    19. Maggs DG, Fineman M, Kornstein J, Burrell T, Schwartz S, Wang Y, Ruggles JA, Kolterman O, Weyer C. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study. Diabetes Metab Res Rev. 2004 Jan-Feb; 20(1):55-60. PMID: 14737746.
      View in: PubMed
    20. Maggs D, Shen L, Strobel S, Brown D, Kolterman O, Weyer C. Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis. Metabolism. 2003 Dec; 52(12):1638-42. PMID: 14669170.
      View in: PubMed
    21. Hollander P, Ratner R, Fineman M, Strobel S, Shen L, Maggs D, Kolterman O, Weyer C. Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets. Diabetes Obes Metab. 2003 Nov; 5(6):408-14. PMID: 14617226.
      View in: PubMed
    22. Weyer C, Gottlieb A, Kim DD, Lutz K, Schwartz S, Gutierrez M, Wang Y, Ruggles JA, Kolterman O, Maggs DG. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study. Diabetes Care. 2003 Nov; 26(11):3074-9. PMID: 14578242.
      View in: PubMed
    23. Kolterman O, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2003 Jul; 88(7):3082-9. PMID: 12843147.
      View in: PubMed
    24. Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, Weyer C, Kolterman O. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2003 Mar; 26(3):784-90. PMID: 12610038.
      View in: PubMed
    25. Levetan C, Want LL, Weyer C, Strobel SA, Crean J, Wang Y, Maggs DG, Kolterman O, Chandran M, Mudaliar SR, Henry RR. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care. 2003 Jan; 26(1):1-8. PMID: 12502651.
      View in: PubMed
    26. Fineman M, Weyer C, Maggs DG, Strobel S, Kolterman O. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. Horm Metab Res. 2002 Sep; 34(9):504-8. PMID: 12384827.
      View in: PubMed
    27. Fineman MS, Koda JE, Shen LZ, Strobel SA, Maggs DG, Weyer C, Kolterman O. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism. 2002 May; 51(5):636-41. PMID: 11979398.
      View in: PubMed
    28. Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, Maggs DG, Weyer C, Kolterman O. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care. 2002 Apr; 25(4):724-30. PMID: 11919132.
      View in: PubMed
    29. Ratner RE, Want LL, Fineman MS, Velte MJ, Ruggles JA, Gottlieb A, Weyer C, Kolterman O. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther. 2002; 4(1):51-61. PMID: 12017421.
      View in: PubMed
    30. Weyer C, Maggs DG, Young AA, Kolterman O. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr Pharm Des. 2001 Sep; 7(14):1353-73. PMID: 11472273.
      View in: PubMed
    31. Young A, Kolterman O, Hall J. Amylin innocent in essential hypertension? Diabetologia. 1999 Aug; 42(8):1029. PMID: 10491767.
      View in: PubMed
    32. Nyholm B, Orskov L, Hove KY, Gravholt CH, Møller N, Alberti KG, Moyses C, Kolterman O, Schmitz O. The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus. Metabolism. 1999 Jul; 48(7):935-41. PMID: 10421239.
      View in: PubMed
    33. Thompson RG, Pearson L, Schoenfeld SL, Kolterman O. Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group. Diabetes Care. 1998 Jun; 21(6):987-93. PMID: 9614619.
      View in: PubMed
    34. Thompson RG, Pearson L, Kolterman O. Effects of 4 weeks' administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations. Diabetologia. 1997 Nov; 40(11):1278-85. PMID: 9389419.
      View in: PubMed
    35. Thompson RG, Gottlieb A, Organ K, Koda J, Kisicki J, Kolterman O. Pramlintide: a human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes. Diabet Med. 1997 Jul; 14(7):547-55. PMID: 9223392.
      View in: PubMed
    36. Kolterman O. Amylin and glycaemic regulation: a possible role for the human amylin analogue pramlintide. Diabet Med. 1997 Jun; 14 Suppl 2:S35-8. PMID: 9212328.
      View in: PubMed
    37. Moyses C, Young A, Kolterman O. Modulation of gastric emptying as a therapeutic approach to glycaemic control. Diabet Med. 1996 Sep; 13(9 Suppl 5):S34-8. PMID: 8894469.
      View in: PubMed
    38. Hanson CL, De Guire MJ, Schinkel AM, Kolterman O, Goodman JP, Buckingham BA. Self-care behaviors in insulin-dependent diabetes: evaluative tools and their associations with glycemic control. J Pediatr Psychol. 1996 Aug; 21(4):467-82. PMID: 8863457.
      View in: PubMed
    39. Dimsdale JE, Kolterman O, Koda J, Nelesen R. Effect of race and hypertension on plasma amylin concentrations. Hypertension. 1996 Jun; 27(6):1273-6. PMID: 8641735.
      View in: PubMed
    40. Kolterman O, Schwartz S, Corder C, Levy B, Klaff L, Peterson J, Gottlieb A. Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Diabetologia. 1996 Apr; 39(4):492-9. PMID: 8778001.
      View in: PubMed
    41. Colburn WA, Gottlieb AB, Koda J, Kolterman O. Pharmacokinetics and pharmacodynamics of AC137 (25,28,29 tripro-amylin, human) after intravenous bolus and infusion doses in patients with insulin-dependent diabetes. J Clin Pharmacol. 1996 Jan; 36(1):13-24. PMID: 8932539.
      View in: PubMed
    42. Hanson CL, De Guire MJ, Schinkel AM, Kolterman O. Empirical validation for a family-centered model of care. Diabetes Care. 1995 Oct; 18(10):1347-56. PMID: 8721936.
      View in: PubMed
    43. Cutler DL, Gray CG, Park SW, Hickman MG, Bell JM, Kolterman O. Low-carbohydrate diet alters intracellular glucose metabolism but not overall glucose disposal in exercise-trained subjects. Metabolism. 1995 Oct; 44(10):1264-70. PMID: 7476282.
      View in: PubMed
    44. Kolterman O, Gottlieb A, Moyses C, Colburn W. Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue. Diabetes Care. 1995 Aug; 18(8):1179-82. PMID: 7587855.
      View in: PubMed
    45. Solt VB, Brown MR, Kennedy B, Kolterman O, Ziegler MG. Elevated insulin, norepinephrine, and neuropeptide Y in hypertension. Am J Hypertens. 1990 Nov; 3(11):823-8. PMID: 2261148.
      View in: PubMed
    46. Garvey WT, Kolterman O. Correlation of in vivo and in vitro actions of insulin in obesity and noninsulin-dependent diabetes mellitus: role of the glucose transport system. Diabetes Metab Rev. 1988 Sep; 4(6):543-69. PMID: 3065009.
      View in: PubMed
    47. Garvey WT, Olefsky JM, Rubenstein AH, Kolterman O. Day-long integrated serum insulin and C-peptide profiles in patients with NIDDM. Correlation with urinary C-peptide excretion. Diabetes. 1988 May; 37(5):590-9. PMID: 3282946.
      View in: PubMed
    48. Wright KS, Beck-Nielsen H, Kolterman O, Mandarino LJ. Decreased activation of skeletal muscle glycogen synthase by mixed-meal ingestion in NIDDM. Diabetes. 1988 Apr; 37(4):436-40. PMID: 2837418.
      View in: PubMed
    49. Moore TR, Hollingsworth DR, Kolterman O, Nager C. Continuous subcutaneous insulin infusion in an obese insulin-resistant pregnant woman with type II diabetes: accelerated fetal growth and neonatal complications. Obstet Gynecol. 1987 Sep; 70(3 Pt 2):480-5. PMID: 3627609.
      View in: PubMed
    50. Baron AD, Eckel RH, Schmeiser L, Kolterman O. The effect of short-term alpha-glucosidase inhibition on carbohydrate and lipid metabolism in type II (noninsulin-dependent) diabetics. Metabolism. 1987 May; 36(5):409-15. PMID: 3553848.
      View in: PubMed
    51. Baron AD, Schaeffer L, Shragg P, Kolterman O. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes. 1987 Mar; 36(3):274-83. PMID: 2879757.
      View in: PubMed
    52. Glauber HS, Revers RR, Henry R, Schmeiser L, Wallace P, Kolterman O, Cohen RM, Rubenstein AH, Galloway JA, Frank BH. In vivo deactivation of proinsulin action on glucose disposal and hepatic glucose production in normal man. Diabetes. 1986 Mar; 35(3):311-7. PMID: 3512341.
      View in: PubMed
    53. Crapo PA, Kolterman O, Henry RR. Metabolic consequence of two-week fructose feeding in diabetic subjects. Diabetes Care. 1986 Mar-Apr; 9(2):111-9. PMID: 3516605.
      View in: PubMed
    54. Henry RR, Wiest-Kent TA, Scheaffer L, Kolterman O, Olefsky JM. Metabolic consequences of very-low-calorie diet therapy in obese non-insulin-dependent diabetic and nondiabetic subjects. Diabetes. 1986 Feb; 35(2):155-64. PMID: 3510922.
      View in: PubMed
    55. Baron AD, Kolterman O, Bell J, Mandarino LJ, Olefsky JM. Rates of noninsulin-mediated glucose uptake are elevated in type II diabetic subjects. J Clin Invest. 1985 Nov; 76(5):1782-8. PMID: 2865274; PMCID: PMC424207.
    56. Kolterman O. Longitudinal evaluation of the effects of sulfonylurea therapy in subjects with type II diabetes mellitus. Am J Med. 1985 Sep 20; 79(3B):23-33. PMID: 3931459.
      View in: PubMed
    57. Garvey WT, Revers RR, Kolterman O, Rubenstein AH, Olefsky JM. Modulation of insulin secretion by insulin and glucose in type II diabetes mellitus. J Clin Endocrinol Metab. 1985 Mar; 60(3):559-68. PMID: 3882736.
      View in: PubMed
    58. Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman O. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes. 1985 Mar; 34(3):222-34. PMID: 3882489.
      View in: PubMed
    59. Fink RI, Revers RR, Kolterman O, Olefsky JM. The metabolic clearance of insulin and the feedback inhibition of insulin secretion are altered with aging. Diabetes. 1985 Mar; 34(3):275-80. PMID: 3882495.
      View in: PubMed
    60. Olefsky JM, Revers RR, Prince M, Henry RR, Garvey WT, Scarlett JA, Kolterman O. Insulin resistance in non-insulin dependent (type II) and insulin dependent (type I) diabetes mellitus. Adv Exp Med Biol. 1985; 189:176-205. PMID: 3898763.
      View in: PubMed
    61. Revers RR, Henry R, Schmeiser L, Kolterman O, Cohen R, Bergenstal R, Polonsky K, Jaspan J, Rubenstein A, Frank B. The effects of biosynthetic human proinsulin on carbohydrate metabolism. Diabetes. 1984 Aug; 33(8):762-70. PMID: 6378699.
      View in: PubMed
    62. Revers RR, Henry R, Schmeiser L, Kolterman O, Cohen R, Rubenstein A, Frank B, Galloway J, Olefsky JM. Biosynthetic human insulin and proinsulin have additive but not synergistic effects on total body glucose disposal. J Clin Endocrinol Metab. 1984 Jun; 58(6):1094-8. PMID: 6373809.
      View in: PubMed
    63. Bergenstal RM, Cohen RM, Lever E, Polonsky K, Jaspan J, Blix PM, Revers R, Olefsky JM, Kolterman O, Steiner K. The metabolic effects of biosynthetic human proinsulin in individuals with type I diabetes. J Clin Endocrinol Metab. 1984 Jun; 58(6):973-9. PMID: 6373814.
      View in: PubMed
    64. Kolterman O, Olefsky JM. The impact of sulfonylurea treatment upon the mechanisms responsible for the insulin resistance in type II diabetes. Diabetes Care. 1984 May-Jun; 7 Suppl 1:81-8. PMID: 6376033.
      View in: PubMed
    65. Kolterman O, Gray RS, Shapiro G, Scarlett JA, Griffin J, Olefsky JM. The acute and chronic effects of sulfonylurea therapy in type II diabetic subjects. Diabetes. 1984 Apr; 33(4):346-54. PMID: 6423429.
      View in: PubMed
    66. Revers RR, Fink R, Griffin J, Olefsky JM, Kolterman O. Influence of hyperglycemia on insulin's in vivo effects in type II diabetes. J Clin Invest. 1984 Mar; 73(3):664-72. PMID: 6368585; PMCID: PMC425067.
    67. Revers RR, Kolterman O, Scarlett JA, Gray RS, Olefsky JM. Lack of in vivo insulin resistance in controlled insulin-dependent, type I, diabetic patients. J Clin Endocrinol Metab. 1984 Feb; 58(2):353-8. PMID: 6363437.
      View in: PubMed
    68. Berhanu P, Kolterman O, Baron A, Tsai P, Olefsky JM, Brandenburg D. Insulin receptors in isolated human adipocytes. Characterization by photoaffinity labeling and evidence for internalization and cellular processing. J Clin Invest. 1983 Dec; 72(6):1958-70. PMID: 6358259; PMCID: PMC437036.
    69. Revers RR, Kolterman O, Olefsky JM. Relationship between serum glucose level and the metabolic clearance rate of glucose in non-insulin-dependent diabetes mellitus. Diabetes. 1983 Jul; 32(7):627-32. PMID: 6345242.
      View in: PubMed
    70. Scarlett JA, Kolterman O, Ciaraldi TP, Kao M, Olefsky JM. Insulin treatment reverses the postreceptor defect in adipocyte 3-O-methylglucose transport in type II diabetes mellitus. J Clin Endocrinol Metab. 1983 Jun; 56(6):1195-201. PMID: 6341390.
      View in: PubMed
    71. Fink RI, Kolterman O, Griffin J, Olefsky JM. Mechanisms of insulin resistance in aging. J Clin Invest. 1983 Jun; 71(6):1523-35. PMID: 6345584; PMCID: PMC370358.
    72. Kolterman O, Prince MJ, Olefsky JM. Insulin resistance in noninsulin-dependent diabetes mellitus: impact of sulfonylurea agents in vivo and in vitro. Am J Med. 1983 Jan 17; 74(1A):82-101. PMID: 6401923.
      View in: PubMed
    73. Ciaraldi TP, Kolterman O, Scarlett JA, Kao M, Olefsky JM. Role of glucose transport in the postreceptor defect of non-insulin-dependent diabetes mellitus. Diabetes. 1982 Nov; 31(11):1016-22. PMID: 6757010.
      View in: PubMed
    74. Crapo PA, Scarlett JA, Kolterman O, Sanders LR, Hofeldt FD, Olefsky JM. The effects of oral fructose, sucrose, and glucose in subjects with reactive hypoglycemia. Diabetes Care. 1982 Sep-Oct; 5(5):512-7. PMID: 6765227.
      View in: PubMed
    75. Crapo PA, Scarlett JA, Kolterman O. Comparison of the metabolic responses to fructose and sucrose sweetened foods. Am J Clin Nutr. 1982 Aug; 36(2):256-61. PMID: 7048890.
      View in: PubMed
    76. Olefsky JM, Kolterman O, Scarlett JA. Insulin action and resistance in obesity and noninsulin-dependent type II diabetes mellitus. Am J Physiol. 1982 Jul; 243(1):E15-30. PMID: 7046470.
      View in: PubMed
    77. Scarlett JA, Kolterman O, Moore P, Saekow M, Insel J, Griffin J, Mako M, Rubenstein AH, Olefsky JM. Insulin resistance and diabetes due to a genetic defect in insulin receptors. J Clin Endocrinol Metab. 1982 Jul; 55(1):123-31. PMID: 7042734.
      View in: PubMed
    78. Scarlett JA, Gray RS, Griffin J, Olefsky JM, Kolterman O. Insulin treatment reverses the insulin resistance of type II diabetes mellitus. Diabetes Care. 1982 Jul-Aug; 5(4):353-63. PMID: 6759075.
      View in: PubMed
    79. Kolterman O, Gray RS, Griffin J, Burstein P, Insel J, Scarlett JA, Olefsky JM. Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus. J Clin Invest. 1981 Oct; 68(4):957-69. PMID: 7287908; PMCID: PMC370882.
    80. Crapo PA, Insel J, Sperling M, Kolterman O. Comparison of serum glucose, insulin, and glucagon responses to different types of complex carbohydrate in noninsulin-dependent diabetic patients. Am J Clin Nutr. 1981 Feb; 34(2):184-90. PMID: 7010982.
      View in: PubMed
    81. Kolterman O, Olefsky JM, Kurahara C, Taylor K. A defect in cell-mediated immune function in insulin-resistant diabetic and obese subjects. J Lab Clin Med. 1980 Sep; 96(3):535-43. PMID: 6995542.
      View in: PubMed
    82. Crapo PA, Kolterman O, Olefsky JM. Effects of oral fructose in normal, diabetic, and impaired glucose tolerance subjects. Diabetes Care. 1980 Sep-Oct; 3(5):575-82. PMID: 7002511.
      View in: PubMed
    83. Crapo PA, Kolterman O, Waldeck N, Reaven GM, Olefsky JM. Postprandial hormonal responses to different types of complex carbohydrate in individuals with impaired glucose tolerance. Am J Clin Nutr. 1980 Aug; 33(8):1723-8. PMID: 6996472.
      View in: PubMed
    84. Insel JR, Kolterman O, Saekow M, Olefsky JM. Short-term regulation of insulin receptor affinity in man. Diabetes. 1980 Feb; 29(2):132-9. PMID: 6986298.
      View in: PubMed
    85. Kolterman O, Greenfield M, Reaven GM, Saekow M, Olefsky JM. Effect of a high carbohydrate diet on insulin binding to adipocytes and on insulin action in vivo in man. Diabetes. 1979 Aug; 28(8):731-6. PMID: 446930.
      View in: PubMed
    86. Kolterman O, Saekow M, Olefsky JM. The effects of acute and chronic starvation on insulin binding to isolated human adipocytes. J Clin Endocrinol Metab. 1979 May; 48(5):836-42. PMID: 429529.
      View in: PubMed
    87. Greenfield M, Kolterman O, Olefsky JM, Reaven GM. The effect of ten days of fasting on various aspects of carbohydrate metabolism in obese diabetic subjects with significant fasting hyperglycemia. Metabolism. 1978 Dec; 27(12 Suppl 2):1839-52. PMID: 723636.
      View in: PubMed
    Orville's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _